Lenalidomide

Key facts

Invented name
Revlimid
Active substance
lenalidomide
Therapeutic area
Oncology
Decision number
P/102/2008
PIP number
Lenalidomide
Pharmaceutical form(s)
hard capsule
Condition(s) / indication(s)
Myelodysplastic Syndrome
Route(s) of administration
Oral use
Contact for public enquiries
Applicant: Celgene Europe Limited
E-mail: medinfo.intl@celgene.com
Country: Switzerland
Phone: +41 327298500
Fax: +41 327298508
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating